Morgan Stanley Entera Bio Ltd. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.55 - $0.74 $550 - $740	1,000 New	1,000 $0
Q3 2023 Nov 15, 2023	SELL	$0.6 - $0.88 $60 - $88	-100 Reduced 9.09%	1,000 $0
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.01 $68 - $101	100 Added 10.0%	1,100 $0
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.05 $17,583 - $36,924	-35,166 Reduced 97.23%	1,000 $0
Q3 2022 Nov 14, 2022	BUY	$0.07 - $1.98 $2,338 - $66,132	33,400 Added 1207.52%	36,166 $38,000
Q2 2022 Oct 27, 2022	SELL	$1.33 - $2.95 $2,912 - $6,460	-2,190 Reduced 44.19%	2,766 $4,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.95 $2,912 - $6,460	-2,190 Reduced 44.19%	2,766 $4,000
Q1 2022 Oct 27, 2022	BUY	$1.91 - $3.23 $4,182 - $7,073	2,190 Added 79.18%	4,956 $14,000
Q1 2022 May 13, 2022	SELL	$1.91 - $3.23 $1,932 - $3,268	-1,012 Reduced 16.96%	4,956 $14,000
Q4 2021 Feb 14, 2022	BUY	$2.82 - $4.79 $1,663 - $2,826	590 Added 10.97%	5,968 $17,000
Q3 2021 Nov 15, 2021	BUY	$4.43 - $6.29 $23,824 - $33,827	5,378 New	5,378 $25,000

5.34M

2.6K

100

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $65.1M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.